Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

Study Overview
=================
Brief Summary
-----------------
It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery. CIK cells transfusion has been reported as an effect therapy in advanced cancers. In another retrospective study, investigators found that adjuvant CIK therapy would prolong the disease-free survival (DFS) for colorectal cancer patients. The purpose of this study is to determine wether adjuvant immunotherapy with CIK cells in patients with colon cancer after operation will prolong DFS, and overall survival (OS).

Official Title
-----------------
Efficacy of Adjuvant Immunotherapy With Cytokine-induced Killer Cells in Patients With Stage II/III Colon Cancer

Conditions
-----------------
Colonic Neoplasms

Intervention / Treatment
-----------------
* Biological: cytokine-induced killer cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colon cancer in stage III or stage II with high risk after R0 resection Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1; Life expectancy of at least 3 months; Normal bone marrow, liver, renal, heart and lung function; Age between 18-80; Patients who provided written informed consent for this study Exclusion Criteria: With uncontrolled other malignant tumors; With uncontrolled infection or tubercle bacillus (TB) or underlying diseases that were severe or life threatening; Patients who need to treat with radiotherapy; Patients who accepted other immunotherapy With sever mental disease or disease with central nervous system (CNS); With the history of organ transplantation, including bone marrow transplantation or stem cell transplantation; Patients with auto immune diseases; pregnant or lactating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: synchronous CIK group<br>After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months. For CapeOx regimen: 3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles. For mFolfox6 regimen: Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles. | Biological: cytokine-induced killer cells<br> <br> * Other names: cytokine induced killer cells;|
| Experimental: sequence CIK group<br>After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later. | Biological: cytokine-induced killer cells<br> <br> * Other names: cytokine induced killer cells;|
| No Intervention: control group<br>After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DFS (Disease free survival) | Patients who were recurrence free at the end of study or lost to follow-up were censored | Time elapsedelapsed from the date of surgery to either the date of recurrence or the date of last follow-up information,whichever come first, assessed up to 5 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS (overall survival) | Patients who were survival at the end of study or lost to follow-up were censored | Time elapsed from the date of surgery to either the date of death or the date of last follow-up information, whichever came first, assessed up to 5 years. | 
| Side effect | Any undesirable secondary effect which occurs in addition to the desired therapeutic effect of CIK or chemotherapy, during the period from the first cycle of chemotherapy or CIK infusion to the end of study. The side effects were described according to the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events) | Up to 2 years | 
| T lymphocyte subset | During the period of CIK infusion | Up to 6 months | 
| QoL (quality of life) | During the period of chemotherapy and CIK infusion | Up to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colon cancer, Cytokine-induced killer cells, Adjuvant immunotherapy, Adjuvant chemotherapy